Compound 2172
Identifiers
- Canonical SMILES:
Cc1cc(N=Nc2ccc(cc2)S(=O)(=O)Nc2ccccn2)c(N)c(C)c1O
- IUPAC name:
4-[2-(2-amino-4-hydroxy-3,5-dimethylphenyl)diazen-1-yl]-N-(pyridin-2-yl)benzene-1-sulfonamide
- InChi:
InChI=1S/C19H19N5O3S/c1-12-11-16(18(20)13(2)19(12)25)23-22-14-6-8-15(9-7-14)28(26,27)24-17-5-3-4-10-21-17/h3-11,25H,20H2,1-2H3,(H,21,24)
- InChiKey:
PJXWUXARDBIOKJ-UHFFFAOYSA-N
External links
![]() 135566900 |
NUE |
External search
![]() |
![]() |
![]() |
![]() |
![]() |
Bibliography (1)
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
4 | 2 | 0 | 1 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
Bromodomain / Histone | 6.82 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 397.12 g/mol | |||
HBA | 8 | |||
HBD | 4 | |||
HBA + HBD | 12 | |||
AlogP | 4.14 | |||
TPSA | 127.23 | |||
RB | 4 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 4 | 2 | 0 | 1 |
Pharmacological data
Bibliography | Name | Target | Competition | Assay type | Assay name | Cell line | Activity type | Activity |
---|---|---|---|---|---|---|---|---|
10.1021/jm401334s | Compound 28, MS267 | BRD4 O60885 |
H4 P62805 |
Biochemical assay | fluorescence anisotropy competition assay using fluorescein-labeled MS417 and BRD4 BrD1 | pKi (inhibition constant, -log10) | 6.82 | |
10.1021/jm401334s | Compound 28, MS267 | BRD4 O60885 |
H4 P62805 |
Biochemical assay | fluorescence anisotropy competition assay using fluorescein-labeled MS417 and BRD4 BrD2 | pKi (inhibition constant, -log10) | 6.36 | |
10.1021/jm401334s | Compound 28, MS267 | BRD4 O60885 |
H4 P62805 |
Biochemical assay | fluorescence anisotropy competition assay using fluorescein-labeled MS574 and BRD3 BrD1 | pKi (inhibition constant, -log10) | 6.54 | |
10.1021/jm401334s | Compound 28, MS267 | BRD4 O60885 |
H4 P62805 |
Biochemical assay | fluorescence anisotropy competition assay using fluorescein-labeled MS574 and BRD3 BrD2 | pKi (inhibition constant, -log10) | 6.66 | |
10.1021/jm401334s | Compound 28, MS267 | BRD4 O60885 |
H4 P62805 |
Cellular assay | Inhibition of BRD4 assessed as inhibition of NF-kappaB-mediated NO production | RAW264.7 cells | pIC50 (half maximal inhibitory concentration, -log10) | 4.42 |
10.1021/jm401334s | Compound 28, MS267 | BRD4 O60885 |
H4 P62805 |
Cellular assay | Inhibition of BRD4 assessed as inhibition of IL-6 expression measured by ELISA | RAW264.7 cells | pIC50 (half maximal inhibitory concentration, -log10) | 4.63 |
Cytotoxicity data
Bibliography | Name | Assay name | Cell line | Compound concentration (μM) | Toxicity |
---|---|---|---|---|---|
10.1021/jm401334s | Compound 28, MS267 | Cell Viability Study of Murine Macrophage Cells | Murinemacrophage RAW264.7 | 50.000 | no |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.8140 | Sulfasalazine | DB00795 | |
0.6460 | Sulfapyridine | DB00891 | |
0.5038 | Sulfaquinoxaline | DB11464 | |
0.5000 | Sulfamethazine | DB01582 | |
0.4919 | Sulfaperin | DB13320 | |
0.4865 | N-{3-METHYL-5-[2-(PYRIDIN-4-YLAMINO)-ETHOXY]-PHENYL}-BENZENESULFONAMIDE | DB07944 | |
0.4846 | Sulfamerazine | DB01581 | |
0.4793 | Sulfadiazine | DB00359 | |
0.4755 | Sulfachlorpyridazine | DB11461 | |
0.4733 | Sulfameter | DB06821 | |
0.4676 | Sulfabromomethazine | DB11547 | |
0.4671 | Sulfaethoxypyridazine | DB11462 | |
0.4662 | Sulfamethoxypyridazine | DB13773 | |
0.4624 | 2-(6-{[(3-chloro-2-methylphenyl)sulfonyl]amino}pyridin-2-yl)-N,N-diethylacetamide | DB07056 | |
0.4610 | ABT-751 | DB12254 |